1. |
Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973-2013)[J]. Ocul Oncol Pathol, 2018, 4(3): 145-151. DOI: 10.1159/000480640.
|
2. |
Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, Ⅲ: initial mortality findings. COMS Report No. 18[J]. Arch Ophthalmol, 2001, 119(7): 969-982. DOI: 10.1001/archopht.119.7.969.
|
3. |
Chen YN, Wang YN, Chen MX, et al. Machine learning models for outcome prediction of Chinese uveal melanoma patients: a 15-year follow-up study[J/OL]. Cancer Commun (Lond), 2022(2022-01-31)[2022-01-09]. https://pubmed.ncbi.nlm.nih.gov/35001563/. DOI: 10.1002/cac2.12253. [published online ahead of print].
|
4. |
Fabian ID, Tomkins-Netzer O, Stoker I, et al. Secondary enucleations for uveal melanoma: a 7-year retrospective analysis[J]. Am J Ophthalmol, 2015, 160(6): 1104-1110. DOI: 10.1016/j.ajo.2015.08.034.
|
5. |
Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study. COMS Report No. 3[J]. Control Clin Trials, 1993, 14(5): 362-391. DOI: 10.1016/0197-2456(93)90052-f.
|
6. |
Astrahan MA, Szechter A, Finger PT. Design and dosimetric considerations of a modified COMS plaque: the reusable "seed-guide" insert[J]. Med Phys, 2005, 32(8): 2706-2716. DOI: 10.1118/1.1993828.
|
7. |
Abramson DH, Servodidio CA, Mccormick B, et al. Changes in height of choroidal melanomas after plaque therapy[J]. Br J Ophthalmol, 1990, 74(6): 359-362. DOI: 10.1136/bjo.74.6.359.
|
8. |
Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: Ⅳ. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS Report No. 19[J]. Ophthalmology, 2002, 109(12): 2197-2206. DOI: 10.1016/s0161-6420(02)01277-0.
|
9. |
Kivela T, Simpson ER, Grossniklaus HE, et al. Uveal melanoma[M]//Amin MB, Edge SB, Greene FL. AJCC cancer staging manual. 8th ed. New York: Springer, 2017: 805-817.
|
10. |
Jager MJ, Shields CL, Cebulla CM, et al. Uveal melanoma[J]. Nat Rev Dis Primers, 2020, 6(1): 24. DOI: 10.1038/s41572-020-0158-0.
|
11. |
Sikuade MJ, Salvi S, Rundle PA, et al. Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma[J]. Eye (Lond), 2015, 29(9): 1194-1198. DOI: 10.1038/eye.2015.109.
|
12. |
Puusaari I, Damato B, Kivelä T. Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height[J]. Graefe's Arch Clin Exp Ophthalmol, 2007, 245(4): 522-533. DOI: 10.1007/s00417-006-0461-9.
|
13. |
Hegde JV, Mccannel TA, Mccannel CA, et al. Juxtapapillary and circumpapillary choroidal melanoma: globe-sparing treatment outcomes with iodine-125 notched plaque brachytherapy[J]. Graefe's Arch Clin Exp Ophthalmol, 2017, 255(9): 1843-1850. DOI: 10.1007/s00417-017-3703-0.
|
14. |
Wen JC, Oliver SC, Mccannel TA. Ocular complications following I-125 brachytherapy for choroidal melanoma[J]. Eye (Lond), 2009, 23(6): 1254-1268. DOI: 10.1038/eye.2009.43.
|
15. |
Shields CL, Shields JA, Karlsson U, et al. Reasons for enucleation after plaque radiotherapy for posterior uveal melanoma. Clinical findings[J]. Ophthalmology, 1989, 96(6): 919-924. DOI: 10.1016/s0161-6420(89)32806-5.
|
16. |
Miguel D, De Frutos-Baraja JM, López-Lara F, et al. Radiobiological doses, tumor, and treatment features influence on outcomes after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part Ⅱ[J]. J Contemp Brachytherapy, 2018, 10(4): 347-359. DOI: 10.5114/jcb.2018.77955.
|
17. |
Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: Ⅳ. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS Report No. 19[J]. Ophthalmology, 2020, 127(4S): S148-157. DOI: 10.1016/j.ophtha.2020.01.032.
|
18. |
Buonanno F, Conson M, De Almeida Ribeiro C, et al. Local tumor control and treatment related toxicity after plaque brachytherapy for uveal melanoma: a systematic review and a data pooled analysis[J]. Radiother Oncol, 2022, 166: 15-25. DOI: 10.1016/j.radonc.2021.11.007.
|
19. |
Shields CL, Naseripour M, Cater J, et al. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients[J]. Ophthalmology, 2002, 109(10): 1838-1849. DOI: 10.1016/s0161-6420(02)01181-8.
|
20. |
Takiar V, Gombos DS, Mourtada F, et al. Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma[J/OL]. Pract Radiat Oncol, 2014, 4(4): e189-e194[2013-09-25]. https://pubmed.ncbi.nlm.nih.gov/25012839/. DOI: 10.1016/j.prro.2013.08.004.
|
21. |
Echegaray JJ, Bechrakis NE, Singh N, et al. Iodine-125 brachytherapy for uveal melanoma: a systematic review of radiation dose[J]. Ocul Oncol Pathol, 2017, 3(3): 193-198. DOI: 10.1159/000455872.
|
22. |
Naseripour M, Jaberi R, Sedaghat A, et al. Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate[J]. J Contemp Brachytherapy, 2016, 8(1): 66-73. DOI: 10.5114/jcb.2016.57818.
|
23. |
Oellers P, Mowery YM, Perez BA, et al. Efficacy and safety of low-dose iodine plaque brachytherapy for juxtapapillary choroidal melanoma[J]. Am J Ophthalmol, 2018, 186: 32-40. DOI: 10.1016/j.ajo.2017.11.008.
|
24. |
Cruess AF, Augsburger JJ, Shields JA, et al. Regression of posterior uveal melanomas following cobalt-60 plaque radiotherapy[J]. Ophthalmology, 1984, 91(12): 1716-1719. DOI: 10.1016/s0161-6420(84)34087-8.
|
25. |
Fang R, Wang H, Li Y, et al. Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy[J]. BMC Ophthalmol, 2021, 21(1): 137. DOI: 10.1186/s12886-021-01898-3.
|
26. |
Luo J, Chen Y, Yang Y, et al. Prognosis prediction of uveal melanoma after plaque brachytherapy based on ultrasound with machine learning[J/OL]. Front Med (Lausanne), 2022, 8: 777142[2022-01-21]. https://pubmed.ncbi.nlm.nih.gov/35127747/. DOI: 10.3389/fmed.2021.777142.
|
27. |
Barker CA, Francis JH, Cohen GN, et al. (106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence[J]. Brachytherapy, 2014, 13(6): 584-590. DOI: 10.1016/j.brachy.2014.04.002.
|
28. |
Perez BA, Mettu P, Vajzovic L, et al. Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes[J]. Int J Radiat Oncol Biol Phys, 2014, 89(1): 127-136. DOI: 10.1016/j.ijrobp.2014.01.026.
|
29. |
Reichstein D, Karan K. Plaque brachytherapy for posterior uveal melanoma in 2018: improved techniques and expanded indications[J]. Curr Opin Ophthalmol, 2018, 29(3): 191-198. DOI: 10.1097/icu.0000000000000468.
|